PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.44%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
14.44%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
12.51%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
12.37%
EPS growth above 1.5x AGEN's 6.72%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
12.37%
Diluted EPS growth above 1.5x AGEN's 6.72%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.24%
OCF growth under 50% of AGEN's 27.67%. Michael Burry might suspect questionable revenue recognition or rising costs.
1.24%
FCF growth under 50% of AGEN's 27.27%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.48%
Negative 10Y OCF/share CAGR while AGEN stands at 26.75%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-6.48%
Negative 5Y OCF/share CAGR while AGEN is at 64.40%. Joel Greenblatt would question the firm’s operational model or cost structure.
-6.48%
Negative 3Y OCF/share CAGR while AGEN stands at 70.32%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-180.68%
Negative 10Y net income/share CAGR while AGEN is at 5.37%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-180.68%
Negative 5Y net income/share CAGR while AGEN is 56.14%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-180.68%
Negative 3Y CAGR while AGEN is 60.08%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-183.69%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-183.69%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-183.69%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.05%
Negative asset growth while AGEN invests at 19.80%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-17.69%
We have a declining book value while AGEN shows 43.67%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
7.69%
Debt growth far above AGEN's 1.41%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
175.10%
SG&A growth well above AGEN's 8.79%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.